Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism

Z. Rosenwaks, M. D. Urban, A. C. Wentz, Peter Lee, T. H. Parmley, C. J. Migeon, G. S. Jones, J. D. Woodruff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

From this study, it appears that total lifetime dose, duration of therapy, and estrogen dose at the time of examination were important factors influencing endometrial histology in patients receiving exogenous estrogens. Our patients were shown to be at statistically greater risk for abnormal endometrial biopsy findings if (1) they had received a lifetime dose of conjugated estrogens ≥2,500 mg, (2) the duration of their estrogen therapy was more than seven years, and (3) their dose of conjugated estrogens at the time of biopsy was > 1.25 mg/day. Almost all of our patients had recieved sequential estrogen-progesterone therapy. The progestational agent given at the dose and in the fashion described above did not appear to protect the patients from development of endometrial pathology. Control groups of patients receiving unopposed estrogens are lacking, and therefore we cannot speculate on whether the incidence of endometrial changes was decreased by the progestational agent. The total lifetime dose of progestational agent was not significantly different in the three grades of endometrial histology despite the fact that the estrogen dose was almost twice as high in the hyperplasia group (grade III) than in groups with normal endometrium (grades I and II). Although both the dose of estrogens and the duration of therapy were found to be statistically important factors increasing risk of endometrial pathology, it remains to be shown whether patients receiving low doses of estrogen for long durations are at risk of developing endometrial abnormalities. On the basis of these data, we would like to suggest that estrogen therapy should be maintained at the lowest possible therapeutic dose level (the level that will maintain regular cyclic bleeding). Further, patients receiving estrogen-progesterone therapy should have endometrial biopsy periodically to determine if there is a silent endometrial abnormality.

Original languageEnglish (US)
Pages (from-to)1184-1188
Number of pages5
JournalPediatrics
Volume62
Issue number6 II SUPPL.
StatePublished - Dec 1 1978

Fingerprint

Hypogonadism
Estrogens
Pathology
Progestins
Therapeutics
Conjugated (USP) Estrogens
Biopsy
Progesterone
Histology
Endometrium
Hyperplasia
Hemorrhage
Control Groups

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Rosenwaks, Z., Urban, M. D., Wentz, A. C., Lee, P., Parmley, T. H., Migeon, C. J., ... Woodruff, J. D. (1978). Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism. Pediatrics, 62(6 II SUPPL.), 1184-1188.
Rosenwaks, Z. ; Urban, M. D. ; Wentz, A. C. ; Lee, Peter ; Parmley, T. H. ; Migeon, C. J. ; Jones, G. S. ; Woodruff, J. D. / Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism. In: Pediatrics. 1978 ; Vol. 62, No. 6 II SUPPL. pp. 1184-1188.
@article{c29d9c4e443d475b8b918d54ccda6759,
title = "Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism",
abstract = "From this study, it appears that total lifetime dose, duration of therapy, and estrogen dose at the time of examination were important factors influencing endometrial histology in patients receiving exogenous estrogens. Our patients were shown to be at statistically greater risk for abnormal endometrial biopsy findings if (1) they had received a lifetime dose of conjugated estrogens ≥2,500 mg, (2) the duration of their estrogen therapy was more than seven years, and (3) their dose of conjugated estrogens at the time of biopsy was > 1.25 mg/day. Almost all of our patients had recieved sequential estrogen-progesterone therapy. The progestational agent given at the dose and in the fashion described above did not appear to protect the patients from development of endometrial pathology. Control groups of patients receiving unopposed estrogens are lacking, and therefore we cannot speculate on whether the incidence of endometrial changes was decreased by the progestational agent. The total lifetime dose of progestational agent was not significantly different in the three grades of endometrial histology despite the fact that the estrogen dose was almost twice as high in the hyperplasia group (grade III) than in groups with normal endometrium (grades I and II). Although both the dose of estrogens and the duration of therapy were found to be statistically important factors increasing risk of endometrial pathology, it remains to be shown whether patients receiving low doses of estrogen for long durations are at risk of developing endometrial abnormalities. On the basis of these data, we would like to suggest that estrogen therapy should be maintained at the lowest possible therapeutic dose level (the level that will maintain regular cyclic bleeding). Further, patients receiving estrogen-progesterone therapy should have endometrial biopsy periodically to determine if there is a silent endometrial abnormality.",
author = "Z. Rosenwaks and Urban, {M. D.} and Wentz, {A. C.} and Peter Lee and Parmley, {T. H.} and Migeon, {C. J.} and Jones, {G. S.} and Woodruff, {J. D.}",
year = "1978",
month = "12",
day = "1",
language = "English (US)",
volume = "62",
pages = "1184--1188",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6 II SUPPL.",

}

Rosenwaks, Z, Urban, MD, Wentz, AC, Lee, P, Parmley, TH, Migeon, CJ, Jones, GS & Woodruff, JD 1978, 'Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism', Pediatrics, vol. 62, no. 6 II SUPPL., pp. 1184-1188.

Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism. / Rosenwaks, Z.; Urban, M. D.; Wentz, A. C.; Lee, Peter; Parmley, T. H.; Migeon, C. J.; Jones, G. S.; Woodruff, J. D.

In: Pediatrics, Vol. 62, No. 6 II SUPPL., 01.12.1978, p. 1184-1188.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism

AU - Rosenwaks, Z.

AU - Urban, M. D.

AU - Wentz, A. C.

AU - Lee, Peter

AU - Parmley, T. H.

AU - Migeon, C. J.

AU - Jones, G. S.

AU - Woodruff, J. D.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - From this study, it appears that total lifetime dose, duration of therapy, and estrogen dose at the time of examination were important factors influencing endometrial histology in patients receiving exogenous estrogens. Our patients were shown to be at statistically greater risk for abnormal endometrial biopsy findings if (1) they had received a lifetime dose of conjugated estrogens ≥2,500 mg, (2) the duration of their estrogen therapy was more than seven years, and (3) their dose of conjugated estrogens at the time of biopsy was > 1.25 mg/day. Almost all of our patients had recieved sequential estrogen-progesterone therapy. The progestational agent given at the dose and in the fashion described above did not appear to protect the patients from development of endometrial pathology. Control groups of patients receiving unopposed estrogens are lacking, and therefore we cannot speculate on whether the incidence of endometrial changes was decreased by the progestational agent. The total lifetime dose of progestational agent was not significantly different in the three grades of endometrial histology despite the fact that the estrogen dose was almost twice as high in the hyperplasia group (grade III) than in groups with normal endometrium (grades I and II). Although both the dose of estrogens and the duration of therapy were found to be statistically important factors increasing risk of endometrial pathology, it remains to be shown whether patients receiving low doses of estrogen for long durations are at risk of developing endometrial abnormalities. On the basis of these data, we would like to suggest that estrogen therapy should be maintained at the lowest possible therapeutic dose level (the level that will maintain regular cyclic bleeding). Further, patients receiving estrogen-progesterone therapy should have endometrial biopsy periodically to determine if there is a silent endometrial abnormality.

AB - From this study, it appears that total lifetime dose, duration of therapy, and estrogen dose at the time of examination were important factors influencing endometrial histology in patients receiving exogenous estrogens. Our patients were shown to be at statistically greater risk for abnormal endometrial biopsy findings if (1) they had received a lifetime dose of conjugated estrogens ≥2,500 mg, (2) the duration of their estrogen therapy was more than seven years, and (3) their dose of conjugated estrogens at the time of biopsy was > 1.25 mg/day. Almost all of our patients had recieved sequential estrogen-progesterone therapy. The progestational agent given at the dose and in the fashion described above did not appear to protect the patients from development of endometrial pathology. Control groups of patients receiving unopposed estrogens are lacking, and therefore we cannot speculate on whether the incidence of endometrial changes was decreased by the progestational agent. The total lifetime dose of progestational agent was not significantly different in the three grades of endometrial histology despite the fact that the estrogen dose was almost twice as high in the hyperplasia group (grade III) than in groups with normal endometrium (grades I and II). Although both the dose of estrogens and the duration of therapy were found to be statistically important factors increasing risk of endometrial pathology, it remains to be shown whether patients receiving low doses of estrogen for long durations are at risk of developing endometrial abnormalities. On the basis of these data, we would like to suggest that estrogen therapy should be maintained at the lowest possible therapeutic dose level (the level that will maintain regular cyclic bleeding). Further, patients receiving estrogen-progesterone therapy should have endometrial biopsy periodically to determine if there is a silent endometrial abnormality.

UR - http://www.scopus.com/inward/record.url?scp=0018231651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018231651&partnerID=8YFLogxK

M3 - Article

C2 - 724357

AN - SCOPUS:0018231651

VL - 62

SP - 1184

EP - 1188

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6 II SUPPL.

ER -

Rosenwaks Z, Urban MD, Wentz AC, Lee P, Parmley TH, Migeon CJ et al. Endometrial pathology and its relation to estrogen therapy in patients with hypogonadism. Pediatrics. 1978 Dec 1;62(6 II SUPPL.):1184-1188.